Avalo Therapeutics, Inc.
Extracted from this filing and checked against the source text.
Avalo Therapeutics, Inc. entered into Underwriting Agreement with SVB Securities LLC and RBC Capital Markets, LLC, as representatives of the several underwriters named therein valued at approximately $15 million (effective 2023-02-02).
On February 2, 2023, Avalo Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with SVB Securities LLC and RBC Capital Markets, LLC, as representatives of the several underwriters named therein (the “Underwriters”), in connection with the public offering (the “Offering”) of an aggregate of 3,770,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share, and warrants to purchase up to an aggregate of 3,770,000 shares of common stock, at a combined price to the public of $3.98 per share and warrant, for aggregate gross proceeds of approximately $15 million, before deducting underwriting discounts and commissions and estimated fees and expenses payable by the Company in connection with the Offering.View on SEC.gov
622 material agreements filed in the last 30 days. Browse all material agreements →
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.